OncoCyte Stock Price, News & Analysis (NYSEAMERICAN:OCX)

$4.20 -0.10 (-2.33 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$4.20
Today's Range$4.20 - $4.34
52-Week Range$3.60 - $7.85
Volume5,558 shs
Average Volume30,093 shs
Market Capitalization$131.99 million
P/E Ratio-6.77
Dividend YieldN/A
BetaN/A

About OncoCyte (NYSEAMERICAN:OCX)

OncoCyte logoOncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone+1-510-7750515

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-6.7741935483871
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.62)
Net IncomeN/A
Net MarginsN/A
Return on Equity-404.76%
Return on Assets-209.93%

Miscellaneous

EmployeesN/A
Outstanding Shares31,430,000

OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) announced its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. View OncoCyte's Earnings History.

When will OncoCyte make its next earnings announcement?

OncoCyte is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for OncoCyte.

Where is OncoCyte's stock going? Where will OncoCyte's stock price be in 2018?

2 analysts have issued 12-month target prices for OncoCyte's shares. Their forecasts range from $7.75 to $7.75. On average, they expect OncoCyte's stock price to reach $7.75 in the next year. View Analyst Ratings for OncoCyte.

Are investors shorting OncoCyte?

OncoCyte saw a increase in short interest during the month of December. As of December 29th, there was short interest totalling 477,222 shares, an increase of 47.1% from the December 15th total of 324,331 shares. Based on an average daily volume of 43,784 shares, the days-to-cover ratio is presently 10.9 days. Approximately 5.7% of the company's shares are sold short.

Who are some of OncoCyte's key competitors?

How do I buy OncoCyte stock?

Shares of OncoCyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoCyte's stock price today?

One share of OncoCyte stock can currently be purchased for approximately $4.20.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $131.99 million.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-7750515.


MarketBeat Community Rating for OncoCyte (OCX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OncoCyte (NYSEAMERICAN:OCX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.75$7.75$7.75$7.75
Price Target Upside: 5.44% upside5.44% upside5.44% upside5.44% upside

OncoCyte (NYSEAMERICAN:OCX) Consensus Price Target History

Price Target History for OncoCyte (NYSEAMERICAN:OCX)

OncoCyte (NYSEAMERICAN:OCX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/23/2017Chardan CapitalBoost Price TargetBuy$6.50 -> $7.75View Rating Details
1/30/2017Canaccord GenuityReiterated RatingBuyView Rating Details
6/7/2016BenchmarkBoost Price TargetSpeculative Buy$7.50 -> $8.00View Rating Details
3/25/2016Lake Street CapitalInitiated CoverageBuy$8.00View Rating Details
3/15/2016Janney Montgomery ScottReiterated RatingBuy$15.00View Rating Details
(Data available from 1/20/2016 forward)

Earnings

OncoCyte (NYSEAMERICAN:OCX) Earnings History and Estimates Chart

Earnings by Quarter for OncoCyte (NYSEAMERICAN:OCX)

OncoCyte (NYSEAMERICAN OCX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.13)N/AView Earnings Details
11/14/2017Q3 2017($0.13)($0.12)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.12)($0.13)ViewN/AView Earnings Details
4/28/2017Q1 2017($0.13)($0.16)ViewN/AView Earnings Details
2/27/2017Q4 2016($0.11)($0.11)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.10)($0.10)ViewN/AView Earnings Details
8/11/2016Q2 2016($0.11)($0.10)ViewN/AView Earnings Details
5/16/2016Q1 2016($0.11)($0.12)ViewN/AView Earnings Details
3/30/2016($0.09)($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

OncoCyte (NYSEAMERICAN:OCX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for OncoCyte (NYSEAMERICAN:OCX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for OncoCyte (NYSEAMERICAN OCX)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

OncoCyte (NYSEAMERICAN OCX) News Headlines

Source:
DateHeadline
OncoCyte (OCX) Lifted to "Buy" at Zacks Investment ResearchOncoCyte (OCX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 13 at 9:26 AM
Short Interest in OncoCyte Co. (OCX) Expands By 47.1%Short Interest in OncoCyte Co. (OCX) Expands By 47.1%
www.americanbankingnews.com - January 10 at 6:04 PM
OncoCyte (OCX) Lowered to "Hold" at Zacks Investment ResearchOncoCyte (OCX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 9 at 9:02 AM
OncoCyte (OCX) Upgraded by Zacks Investment Research to BuyOncoCyte (OCX) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 6 at 9:56 AM
What Is The Future Prospect For Healthcare And OncoCyte Corporation (NYSEMKT:OCX)?What Is The Future Prospect For Healthcare And OncoCyte Corporation (NYSEMKT:OCX)?
finance.yahoo.com - January 5 at 10:20 AM
OncoCyte Co. (OCX) Short Interest Up 58.5% in NovemberOncoCyte Co. (OCX) Short Interest Up 58.5% in November
www.americanbankingnews.com - December 11 at 7:58 PM
OncoCyte Presents Positive Data from its Liquid Biopsy Breast Cancer Diagnostic Test at the San Antonio Breast Cancer SymposiumOncoCyte Presents Positive Data from its Liquid Biopsy Breast Cancer Diagnostic Test at the San Antonio Breast Cancer Symposium
finance.yahoo.com - December 7 at 8:55 AM
Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS ConferenceAdditional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference
www.businesswire.com - December 4 at 8:50 AM
OncoCyte Initiates Search for New Independent DirectorOncoCyte Initiates Search for New Independent Director
finance.yahoo.com - November 29 at 5:01 PM
OncoCyte Corporation to Participate in the Benchmark Company, LLC Micro Cap Discovery One-on-One ConferenceOncoCyte Corporation to Participate in the Benchmark Company, LLC Micro Cap Discovery One-on-One Conference
finance.yahoo.com - November 27 at 4:42 PM
Seasoned Financial Executive Joins OncoCyte as Chief Financial OfficerSeasoned Financial Executive Joins OncoCyte as Chief Financial Officer
finance.yahoo.com - November 18 at 10:08 AM
OncoCyte Corp (OCX) Lowered to Sell at Zacks Investment ResearchOncoCyte Corp (OCX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 18 at 6:06 AM
BRIEF-Oncocyte Q3 loss per share $0.22BRIEF-Oncocyte Q3 loss per share $0.22
www.reuters.com - November 15 at 7:02 AM
OncoCytes (OCX) CEO Bill Annett on Q3 2017 Results - Earnings Call TranscriptOncoCyte's (OCX) CEO Bill Annett on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 7:02 AM
OncoCyte Reports Third Quarter 2017 Financial ResultsOncoCyte Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 7:02 AM

SEC Filings

OncoCyte (NYSEAMERICAN:OCX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OncoCyte (NYSEAMERICAN:OCX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OncoCyte (NYSEAMERICAN OCX) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.